Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options
1 Georges Pompidou European Hospital (AP-HP), 2 King's College Hospital, London, UK and 3 Hôtel Dieu Hospital (AP-HP), Paris, France
Correspondence and offprint requests to: Jérôme Rossert, MD, PhD, Department of Nephrology, Georges Pompidou European Hospital (AP-HP), 20 rue Leblanc, 75015 Paris, France. Email: jerome.rossert{at}egp.aphp.fr
In the vast majority of patients with antibody (Ab)-mediated pure red cell aplasia (PRCA), simple withdrawal of the erythropoiesis-stimulating agent (ESA) does not effectively reverse PRCA. In contrast, immunosuppressive treatments can induce the disappearance of anti-erythropoietin Abs and a reversal of PRCA. Consensus opinion on the optimal therapy has not been established, but individual case reports or case series suggest that kidney transplantation or treatment with corticosteroids plus cyclophosphamide are the most effective therapies. However, treatment with cyclosporine is an interesting alternative, since it appears to be effective in at least two-thirds of patients and with minimal side effects. Due to the key role of ESAs in the management of patients with chronic kidney disease (CKD), some patients have been re-treated with an ESA following resolution of Ab-mediated PRCA. In all reported cases, this treatment increased haemoglobin levels, alleviated the need for transfusions and did not have side effects. However, one should be extremely cautious when deciding to re-treat a patient with ESA, due to the small number of reported cases and the possibility of publication bias.
Keywords: epoetin; erythropoietin; immunosuppression; outcomes; pure red cell aplasia